Publications by authors named "Joaquin Mateo"

64Publications

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

N Engl J Med 2020 Sep 20. Epub 2020 Sep 20.

From the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.); Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital, Barcelona (J.M.), the Spanish National Cancer Research Center, Madrid (D.O.), and Instituto de Investigación Biomédica de Málaga, Málaga (D.O.) - all in Spain; Institut Gustave Roussy, University of Paris Saclay, Villejuif (K.F.), the Department of Medical Oncology, Centre Hospitalier Universitaire Besançon, Besançon (A.T.-V.), and the Department of Medical Oncology, Institut Bergonié, Bordeaux (G.R.) - all in France; Centre Hospitalier de l'Université de Montréal-Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal (F.S.), and BC Cancer Agency, Vancouver (K.N.C.) - both in Canada; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S.S.); Tulane University School of Medicine, New Orleans (O.S.); Huntsman Cancer Institute, University of Utah, Salt Lake City (N.A.); John Wayne Cancer Institute, Santa Monica, CA (P.T.); Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, Turkey (M.O.); AstraZeneca, Global Medicines Development, Oncology, Gaithersburg, MD (J.K.); Merck, Kenilworth, NJ (J.B.); and Global Medicines Development, Oncology (C.G.), Precision Medicine and Biosamples, R&D Oncology (C.C.), and Translational Medicine (C.A.A.), AstraZeneca, Cambridge, and the Institute of Cancer Research and Royal Marsden, London (J.B.) - both in the United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa2022485DOI Listing
September 2020

Olaparib for Metastatic Castration-Resistant Prostate Cancer.

N Engl J Med 2020 05 28;382(22):2091-2102. Epub 2020 Apr 28.

From the Institute of Cancer Research and Royal Marsden Hospital, London (J. de Bono), and AstraZeneca, Translational Medicine, Cambridge (C.A.A.) - all in the United Kingdom; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital, Barcelona (J.M.), the Spanish National Cancer Research Center, Madrid (D.O.), and Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Malaga (D.O.) - all in Spain; Institut Gustave Roussy, University of Paris Sud, Villejuif (K.F.), and the Department of Medical Oncology, Centre Hospitalier Universitaire Besançon, Besançon (A.T.-V.) - all in France; Centre Hospitalier de l'Université de Montréal-Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal (F.S.), and BC Cancer Agency, Vancouver (K.N.C.) - all in Canada; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S.S.); Tulane University School of Medicine, New Orleans (O.S.); Huntsman Cancer Institute, University of Utah Comprehensive Cancer Center, Salt Lake City (N.A.); John Wayne Cancer Institute, Santa Monica, CA (P.T.); Radboud University Medical Center, Nijmegen, the Netherlands (N.M.); AstraZeneca, Global Medicines Development, Oncology, Gaithersburg, MD (C.G., J.K., W.W.); Merck, Kenilworth, NJ (J. Burgents); AstraZeneca, Precision Medicine, Oncology Research and Development, Gaithersburg, MD (A.K.); and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1911440DOI Listing
May 2020

The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor.

Cancer Treat Rev 2020 Jun 13;86:102000. Epub 2020 Mar 13.

Vall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2020.102000DOI Listing
June 2020

Germline and Somatic Defects in DNA Repair Pathways in Prostate Cancer.

Adv Exp Med Biol 2019 ;1210:279-300

Vall d'Hebron Institute of Oncology, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-030-32656-2_12DOI Listing
February 2020

Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?

ESMO Open 2019 9;4(2):e000480. Epub 2019 May 9.

High Risk and Cancer Prevention Group, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2018-000480DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555601PMC
May 2019

Nanoparticles as theranostic vehicles in prostate cancer.

Ann Transl Med 2019 Mar;7(Suppl 1):S29

Vall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2019.01.77DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462597PMC
March 2019

PARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers.

Eur Urol 2019 10 4;76(4):459-460. Epub 2019 Apr 4.

The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2019.03.029DOI Listing
October 2019

Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer.

Curr Oncol Rep 2019 03 27;21(5):42. Epub 2019 Mar 27.

Prostate Cancer Translational Research Group, Vall d'Hebron Institute of Oncology (VHIO), Cellex Center, Natzaret 115-117, 08035, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0790-6DOI Listing
March 2019

BRCA2 and Other DDR Genes in Prostate Cancer.

Cancers (Basel) 2019 Mar 12;11(3). Epub 2019 Mar 12.

Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Center, 28029 Madrid, Spain.

View Article

Download full-text PDF

Source
https://www.mdpi.com/2072-6694/11/3/352
Publisher Site
http://dx.doi.org/10.3390/cancers11030352DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468860PMC
March 2019

Towards a New Classification for Metastatic Prostate Cancer.

Eur Urol 2019 03 19;75(3):383-384. Epub 2018 Nov 19.

Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.10.058DOI Listing
March 2019

Managing Nonmetastatic Castration-resistant Prostate Cancer.

Eur Urol 2019 02 14;75(2):285-293. Epub 2018 Aug 14.

The Royal Marsden Hospital and The Institute of Cancer Research, London, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.07.035DOI Listing
February 2019

Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey.

Eur Urol Focus 2018 03 10;4(2):235-244. Epub 2016 Oct 10.

Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2016.09.005DOI Listing
March 2018

Biomarkers for Metastatic Castration-resistant Prostate Cancer (mCRPC): Yes or No? Predictive and Response Biomarkers Towards Precision Medicine in mCRPC.

Authors:
Joaquin Mateo

Eur Urol Focus 2016 Dec 12;2(5):465-466. Epub 2016 Jul 12.

The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2016.06.017DOI Listing
December 2016

Targeting DNA damage response systems to impact cancer care.

Curr Probl Cancer 2017 Jul - Aug;41(4):247-250. Epub 2017 Apr 24.

Division of Cancer Therapeutics and Clinical Studies, The Institute of Cancer Research, London, UK; Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.currproblcancer.2017.04.001DOI Listing
April 2017

Investigating Genomic Aberrations of the Androgen Receptor: Moving Closer to More Precise Prostate Cancer Care?

Eur Urol 2017 08 21;72(2):201-204. Epub 2017 Feb 21.

The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.02.005DOI Listing
August 2017

DNA Repair in Prostate Cancer: Biology and Clinical Implications.

Eur Urol 2017 03 31;71(3):417-425. Epub 2016 Aug 31.

Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, London, UK; Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2016.08.037DOI Listing
March 2017

Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer.

Cancer J 2016 Sep/Oct;22(5):353-356

From the *Prostate Cancer Unit, Spanish National Cancer Research Centre (CNIO); and †HM Hospitales-Centro Integral Oncológico HM Clara Campal, Madrid, Spain; ‡Divisions of Cancer Therapeutics and Clinical Studies, The Institute of Cancer Research; and §Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, United Kingdom; and ∥CNIO-IBIMA Genitourinary Cancer Unit at Hospital Virgen de la Victoria and Hospital Regional de Malaga, Malaga, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000219DOI Listing
August 2017

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

N Engl J Med 2016 Aug 6;375(5):443-53. Epub 2016 Jul 6.

From the University of Washington (C.C.P., M. Beightol, C.M., B.N., H.H.C., B.M., T.W., S. Casadei, P.S.N.) and Fred Hutchinson Cancer Research Center (N.D.S., R.G., P.S.N.) - both in Seattle; the Institute of Cancer Research and Royal Marsden Hospital, London (J.M., S. Carreira, R.E., J.B.); Memorial Sloan Kettering Cancer Center (M.F.W., W.A., M. Berger, L.Z., A.Z., J. Vijai, H.I.S., C.S., N.S., P.W.K., D.S., M.R., K.O.), Weill Cornell Medical College (H.B., O.E., M.A.R.), and the Prostate Cancer Clinical Trials Consortium (J. Vinson, J.F.) - all in New York; the University of Michigan, Ann Arbor (D.R., R.L., M.H., A.C.); Howard Hughes Medical Institute, Chevy Chase, MD (A.C., C.S.); and Dana-Farber Cancer Institute, Boston (A.G., L.G., M.-E.T., S.A., G.C.H., E.M.V.A.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1603144DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986616PMC
August 2016

Interrogating the Cancer Genome to Deliver More Precise Cancer Care.

Am Soc Clin Oncol Educ Book 2016 ;35:e577-83

From The Institute of Cancer Research, Sutton, United Kingdom; The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_156908DOI Listing
January 2017

Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses.

Clin Genitourin Cancer 2016 12 5;14(6):485-493. Epub 2016 May 5.

Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden National Health Services Foundation Trust and The Institute of Cancer Research, Sutton, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2016.04.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132155PMC
December 2016

Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer.

Radiology 2016 07 25;280(1):151-60. Epub 2016 Jan 25.

From the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Cancer Therapeutics Division, 15 Cotswold Rd, Sutton SM2 5NG, England.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2015150799DOI Listing
July 2016

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

N Engl J Med 2015 Oct;373(18):1697-708

From the Institute of Cancer Research (J.M., S.C., S.S., S.M., H.M., R.P.-L., D.N.R., A.O., N.T., G.B., N.P., P.F., A.G., I.F., C.P., G.S., D.B., J.G., Z.Z., C.T.W., R.F., R.R., B.E., G.F., D. Roda, W.Y., R.B., H.P., R.A., A.S., R.E., G.A., C.J.L., A.A., E.H., J.S.B.), the Royal Marsden NHS Foundation Trust (J.M., S.S., R.P.-L., A.O., N.T., D.B., Z.Z., R.F., D. Roda, R.E., G.A., J.S.B.), and University College London Hospital (U.M.), London, Queen's University, Belfast (S.J.), University of Leeds, Leeds (C.R.), Churchill Hospital, Oxford (A.P.), University of Liverpool, Liverpool (S.H.), Beatson West of Scotland Cancer Centre, Glasgow (R.J.), and Christie Hospital, Manchester (T.E.) - all in the United Kingdom; the University of Michigan, Ann Arbor (D. Robinson, Y.-M.W., X.C., L.P.K., F.Y.F., A.M.C.); Weill Cornell Medical College, New York (M.A.R.); and Thomas Jefferson University, Philadelphia (K.E.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1506859DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228595PMC
October 2015

Sequencing of agents in castration-resistant prostate cancer.

Lancet Oncol 2015 Jun 27;16(6):e279-92. Epub 2015 May 27.

Prostate Cancer Targeted Therapy Group, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)70033-1DOI Listing
June 2015

Integrative clinical genomics of advanced prostate cancer.

Cell 2015 May;161(5):1215-1228

Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2015.05.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484602PMC
May 2015

Switching and withdrawing hormonal agents for castration-resistant prostate cancer.

Nat Rev Urol 2015 Jan;12(1):37-47

Prostate Cancer Targeted Therapy Group, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrurol.2014.345DOI Listing
January 2015

Molecular characterization and clinical utility of circulating tumor cells in the treatment of prostate cancer.

Am Soc Clin Oncol Educ Book 2014 :e197-203

From the Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, Sutton, Surrey, UK; Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2014.34.e197DOI Listing
November 2015

Novel drugs targeting the androgen receptor pathway in prostate cancer.

Cancer Metastasis Rev 2014 Sep;33(2-3):567-79

Drug Development Unit, Division of Cancer Therapeutics and Division of Clinical Studies, The Royal Marsden NHS Foundation Trust - The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-013-9472-2DOI Listing
September 2014

Appraising iniparib, the PARP inhibitor that never was--what must we learn?

Nat Rev Clin Oncol 2013 Dec 15;10(12):688-96. Epub 2013 Oct 15.

Drug Development Unit, Division of Cancer Therapeutics and Division of Clinical Studies, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrclinonc.2013.177
Publisher Site
http://dx.doi.org/10.1038/nrclinonc.2013.177DOI Listing
December 2013

Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.

Mol Diagn Ther 2012 Jun;16(3):151-61

Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/11632590-000000000-00000DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872147PMC
June 2012

Opportunities and pitfalls of targeted therapeutic combinations in solid tumors.

Am Soc Clin Oncol Educ Book 2012 :670-4

From the Drug Development Unit, Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Downs Road, Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2012.32.191DOI Listing
April 2016

Evaluation of two HbA1c point-of-care analyzers.

Clin Chem Lab Med 2011 Apr 17;49(4):653-7. Epub 2011 Feb 17.

Clinical Biochemistry Department, Virgen Macarena University Hospital, Seville, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/CCLM.2011.101DOI Listing
April 2011

Glycated hemoglobin vs. the oral glucose tolerance test for the exclusion of impaired glucose tolerance in high-risk individuals.

Clin Chem Lab Med 2010 Dec 17;48(12):1719-22. Epub 2010 Sep 17.

Clinical Biochemistry Department, Virgen Macarena University Hospital, Sevilla, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/CCLM.2010.338DOI Listing
December 2010